Man Group PLC Zymeworks Inc. Transaction History

Man Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.43 $332,684 - $531,579	71,545 Added 80.39%	160,545 $987,000
Q2 2022 Aug 15, 2022	BUY	$4.82 - $7.7 $118,572 - $189,420	24,600 Added 38.2%	89,000 $472,000
Q1 2022 May 16, 2022	BUY	$6.0 - $16.98 $386,400 - $1.09 Million	64,400 New	64,400 $422,000
Q3 2020 Nov 16, 2020	SELL	$29.21 - $46.58 $345,758 - $551,367	-11,837 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$33.67 - $40.0 $398,551 - $473,480	11,837 New	11,837 $427,000
Q1 2020 May 15, 2020	SELL	$24.28 - $49.8 $1.08 Million - $2.21 Million	-44,294 Closed	0 $0
Q4 2019 Feb 18, 2020	BUY	$24.84 - $45.46 $1.1 Million - $2.01 Million	44,294 New	44,294 $2.01 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $766M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.